Future directions in myelodysplastic syndrome

Newer agents and the role of combination approaches

Steven D. Gore, Evelyn R. Hermes-DeSantis

Research output: Contribution to journalArticle

Abstract

Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improved overall survival (24.4 months vs 15 months) in high-risk MDS patients receiving azacitidine plus best supportive care vs conventional care which has resulted in an updated label for this product. Conventional care consisted of supportive care alone or either low-dose ara-C or standard chemotherapy plus best supportive care. While these data are encouraging, newer agents such as vorinostat, MGCD0103, MS-275, and tipifarnib are currently being studied as monotherapy or in combinations with approved treatments for MDS. The goal of combining pharmacotherapy, such as the combination of DNA methylation inhibitors and histone deacetylase inhibitors, in the management of MDS is to increase the response rates and decrease the toxicities associated with treatment. Clinical experience in the use of combination products has given practitioners the empirical knowledge necessary to better treat patients with MDS. Utilizing convergent or complementary molecular mechanisms with in vitro or in vivo evidence of synergy is a fresher and maybe a more efficacious approach to combination therapy.

Original languageEnglish (US)
Pages (from-to)40-49
Number of pages10
JournalCancer Control
Volume15
Issue number4 SUPPL.
StatePublished - Oct 2008

Fingerprint

Myelodysplastic Syndromes
Azacitidine
decitabine
tipifarnib
Drug Therapy
Histone Deacetylase Inhibitors
Cytarabine
DNA Methylation
United States Food and Drug Administration
Therapeutics
Direction compound
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Future directions in myelodysplastic syndrome : Newer agents and the role of combination approaches. / Gore, Steven D.; Hermes-DeSantis, Evelyn R.

In: Cancer Control, Vol. 15, No. 4 SUPPL., 10.2008, p. 40-49.

Research output: Contribution to journalArticle

Gore, SD & Hermes-DeSantis, ER 2008, 'Future directions in myelodysplastic syndrome: Newer agents and the role of combination approaches', Cancer Control, vol. 15, no. 4 SUPPL., pp. 40-49.
Gore, Steven D. ; Hermes-DeSantis, Evelyn R. / Future directions in myelodysplastic syndrome : Newer agents and the role of combination approaches. In: Cancer Control. 2008 ; Vol. 15, No. 4 SUPPL. pp. 40-49.
@article{b698776880bf4202bb42a60784721dcf,
title = "Future directions in myelodysplastic syndrome: Newer agents and the role of combination approaches",
abstract = "Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improved overall survival (24.4 months vs 15 months) in high-risk MDS patients receiving azacitidine plus best supportive care vs conventional care which has resulted in an updated label for this product. Conventional care consisted of supportive care alone or either low-dose ara-C or standard chemotherapy plus best supportive care. While these data are encouraging, newer agents such as vorinostat, MGCD0103, MS-275, and tipifarnib are currently being studied as monotherapy or in combinations with approved treatments for MDS. The goal of combining pharmacotherapy, such as the combination of DNA methylation inhibitors and histone deacetylase inhibitors, in the management of MDS is to increase the response rates and decrease the toxicities associated with treatment. Clinical experience in the use of combination products has given practitioners the empirical knowledge necessary to better treat patients with MDS. Utilizing convergent or complementary molecular mechanisms with in vitro or in vivo evidence of synergy is a fresher and maybe a more efficacious approach to combination therapy.",
author = "Gore, {Steven D.} and Hermes-DeSantis, {Evelyn R.}",
year = "2008",
month = "10",
language = "English (US)",
volume = "15",
pages = "40--49",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Future directions in myelodysplastic syndrome

T2 - Newer agents and the role of combination approaches

AU - Gore, Steven D.

AU - Hermes-DeSantis, Evelyn R.

PY - 2008/10

Y1 - 2008/10

N2 - Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improved overall survival (24.4 months vs 15 months) in high-risk MDS patients receiving azacitidine plus best supportive care vs conventional care which has resulted in an updated label for this product. Conventional care consisted of supportive care alone or either low-dose ara-C or standard chemotherapy plus best supportive care. While these data are encouraging, newer agents such as vorinostat, MGCD0103, MS-275, and tipifarnib are currently being studied as monotherapy or in combinations with approved treatments for MDS. The goal of combining pharmacotherapy, such as the combination of DNA methylation inhibitors and histone deacetylase inhibitors, in the management of MDS is to increase the response rates and decrease the toxicities associated with treatment. Clinical experience in the use of combination products has given practitioners the empirical knowledge necessary to better treat patients with MDS. Utilizing convergent or complementary molecular mechanisms with in vitro or in vivo evidence of synergy is a fresher and maybe a more efficacious approach to combination therapy.

AB - Myelodysplastic syndrome (MDS) is not a single disease, but a collection of hematopoietic disorders that require newer strategies. Currently, azacitidine, decitabine, and lenalidomide are approved by the US Food and Drug Administration for the treatment of MDS. A recent study demonstrated an improved overall survival (24.4 months vs 15 months) in high-risk MDS patients receiving azacitidine plus best supportive care vs conventional care which has resulted in an updated label for this product. Conventional care consisted of supportive care alone or either low-dose ara-C or standard chemotherapy plus best supportive care. While these data are encouraging, newer agents such as vorinostat, MGCD0103, MS-275, and tipifarnib are currently being studied as monotherapy or in combinations with approved treatments for MDS. The goal of combining pharmacotherapy, such as the combination of DNA methylation inhibitors and histone deacetylase inhibitors, in the management of MDS is to increase the response rates and decrease the toxicities associated with treatment. Clinical experience in the use of combination products has given practitioners the empirical knowledge necessary to better treat patients with MDS. Utilizing convergent or complementary molecular mechanisms with in vitro or in vivo evidence of synergy is a fresher and maybe a more efficacious approach to combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=55049098618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049098618&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 40

EP - 49

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 4 SUPPL.

ER -